TNF and retinitis pigmentosa 1: TNF-α Inhibitors: Adalimumab, as a TNF-α blocker, has been suggested as a potential therapy to reduce neuroinflammation and photoreceptor apoptosis in RP, though more clinical studies are needed [30].